Better Therapeutics, Inc. (BTTX): Price and Financial Metrics
GET POWR RATINGS... FREE!
BTTX Stock Price Chart Interactive Chart >
BTTX Price/Volume Stats
| Current price | $1.37 | 52-week high | $5.10 |
| Prev. close | $1.31 | 52-week low | $0.91 |
| Day low | $1.32 | Volume | 9,579 |
| Day high | $1.44 | Avg. volume | 25,440 |
| 50-day MA | $1.38 | Dividend yield | N/A |
| 200-day MA | $1.62 | Market Cap | 32.53M |
Better Therapeutics, Inc. (BTTX) Company Bio
As of October 29, 2021, Mountain Crest Acquisition Corp. II was acquired by Better Therapeutics, Inc., in a reverse merger transaction. Mountain Crest Acquisition Corp. II. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or related business combination with one or more businesses. The company was incorporated in 2020 and is based in New York, New York.
Latest BTTX News From Around the Web
Below are the latest news stories about BETTER THERAPEUTICS INC that investors may wish to consider to help them evaluate BTTX as an investment opportunity.
Better Therapeutics Posts Encouraging Data Establishing Proof-Of-Concept For Prescription Digital Therapy PlatformFull story available on Benzinga.com |
Better Therapeutics Completes Exploratory Trial for Fatty Liver Disease and Announces Positive Topline ResultsBetter Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing cognitive behavioral therapy (CBT) to address t |
Better Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)SAN FRANCISCO--(BUSINESS WIRE)--Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics company developing a novel form of cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today announced that the compensation committee of Better Therapeutics’ board of directors approved the grant of a nonqualified stock option exercisable for 200,000 shares of Better Therapeutics’ common stock to Diane Gomez-Thinnes, Chief Commercial Officer, under the |
Industries - Better Therapeutics versus Its Competitors Financial ReviewBetter Therapeutics is one of 33 public companies in the “Health services” industry, but how does it compare to its competitors? We will compare Better Therapeutics to related… |
Better Therapeutics to Participate in BTIG Digital Health ForumSAN FRANCISCO, November 15, 2022--Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics company developing a novel form of cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today announced that Frank Karbe, Chief Executive Officer, and Mark Berman, MD, Chief Medical Officer, will participate in a virtual fireside chat at the BTIG Digital Health Forum on Monday, November 21, 2022, at 2:00 p.m. ET / 11:00 a.m. PT. Better Therapeutics manag |
BTTX Price Returns
| 1-mo | 23.98% |
| 3-mo | -6.80% |
| 6-mo | -33.17% |
| 1-year | -64.51% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 23.98% |
| 2022 | -76.24% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...